IXICO PLC (LON:IXI) has been awarded an expansion contract by a current biopharmaceutical client to support the company's Phase II Alzheimer's disease clinical trial.
The clinical trial will investigate the efficacy, safety and tolerability of an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer's disease.
For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and arterial spin labelling (ASL).
The study is worth in excess of £1mln over five years.
Lammert Albers, IXICO’s chief commercial officer, said: "IXICO is delighted to be awarded the contract for this Alzheimer's disease clinical trial. With no available therapies to address the underlying disease pathology, Alzheimer's disease remains a critical area of unmet medical need.”